Allergan Seeks To Extend Botox Use To Overactive Bladder
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.
You may also be interested in...
A Headache For Map: Levadex Gets “Complete Response” Letter From FDA
The agency raised issues related to the chemistry, manufacturing and controls section of the dihydroergotamine NDA, as well as concerns stemming from inspection of a third-party manufacturing facility, the company says.
Allergan And MAP Team Up On Inhalable Migraine Treatment
Deal with Allergan focuses on detailing to neurologists and pain specialists, leaving MAP free to do other co-promotion deals.
Botox For Migraine: How Will The Market Size Up?
The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.